Latin America Cardiac Marker Testing Market (2026-2031)
The Latin America Cardiac Marker Testing Market was valued at $436.9 Million in 2026 and projected to reach to $678.2 Million by 2031, representing a compound annual growth rate of 9.2%. Latin America's cardiac marker testing market is positioned for sustained growth through 2031, driven by demographic shifts toward an aging population and increasing cardiovascular disease prevalence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America Cardiac Marker Testing Market Trends and Insights
- Latin America's market expansion is driven by rising cardiovascular disease prevalence, increasing healthcare infrastructure investment, and growing adoption of point-of-care testing technologies across the region.
- In Latin America, the shift toward early diagnosis and preventive cardiology is accelerating demand for high-sensitivity troponin assays and multiplex testing platforms. Latin America's cardiac marker testing sector benefits from improving reimbursement policies and regulatory harmonization across major markets including Brazil, Mexico, and Argentina.
- The region's healthcare providers in Latin America are increasingly integrating automated laboratory systems and digital health solutions to enhance diagnostic accuracy and patient outcomes.
- Between 2026 and 2031, Latin America is expected to see significant penetration of advanced biomarker testing in both urban tertiary care centers and emerging secondary care facilities, supporting the projected 9.2% compound annual growth rate..
Key Market Statistics
- CAGR (2026-2031) 9.2% CAGR
- Market Size, 2026 ~USD 436.9 Million
- Forecast, 2031 ~USD 678.2 Million
- Geography Latin America
Latin America Cardiac Marker Testing Market Overview
Market Valuation & Growth Trajectory :
Latin America's cardiac marker testing market is valued at USD 436.9 million in 2026, with a projected expansion to USD 678.2 million by 2031, representing a robust 9.2% CAGR. This growth outpaces many emerging markets and reflects increasing healthcare modernization across the region.
Rising Cardiovascular Disease Burden :
Cardiovascular diseases remain a leading cause of mortality in Latin America, driving demand for early diagnostic solutions. Increased prevalence of hypertension, diabetes, and obesity is accelerating the adoption of cardiac marker testing as a critical preventive healthcare measure.
Point-of-Care Testing Adoption :
Latin American healthcare providers are rapidly adopting point-of-care testing technologies for cardiac markers, enabling faster diagnosis and treatment decisions. This shift improves patient outcomes in both urban hospitals and rural healthcare facilities across the region.
Healthcare Infrastructure Investment :
Governments and private healthcare systems in Latin America are significantly investing in diagnostic infrastructure and laboratory capabilities. These investments are expanding access to cardiac marker testing in underserved populations and strengthening regional healthcare networks.
Latin America Cardiac Marker Testing Market Dynamics
- Healthcare modernization initiatives across major economies like Brazil and Mexico are expanding laboratory capacity and diagnostic accessibility, particularly in emerging urban centers. The region's market expansion will be supported by growing healthcare expenditure, rising awareness of early cardiac disease detection, and technological adoption of automated testing platforms.
- Point-of-care testing solutions are expected to gain significant traction, improving diagnostic speed in both primary care and emergency settings.
- Strategic partnerships between international diagnostic companies and local healthcare providers will further accelerate market penetration across Latin America..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- Latin America's cardiac marker testing market will grow from USD 436.9 million (2026) to USD 678.2 million (2031), representing a 9.2% CAGR.
- Rising cardiovascular disease burden and improved healthcare access in Latin America are primary drivers of market expansion through 2031.
- Latin America is witnessing increased adoption of high-sensitivity troponin and multiplex biomarker assays in both public and private healthcare settings.
- Brazil, Mexico, and Argentina lead Latin America's market growth, supported by regulatory improvements and digital health integration initiatives.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
Latin America Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers of cardiac marker testing platforms and analyzers need Latin America-specific market data to identify expansion opportunities, assess competitive positioning, and develop region-appropriate product strategies for the growing diagnostic market.
- Healthcare System Administrators : Hospital networks and healthcare system leaders in Latin America require market insights to justify laboratory infrastructure investments, benchmark diagnostic capabilities against regional standards, and optimize cardiac testing service offerings.
- In Vitro Diagnostics (IVD) Companies : IVD manufacturers and reagent suppliers need detailed Latin America market analysis to guide product portfolio decisions, identify distribution partnerships, and develop pricing strategies aligned with regional healthcare economics and reimbursement models.
- Healthcare Investors & Private Equity : Investment firms evaluating healthcare opportunities in Latin America require comprehensive market data on cardiac diagnostics to assess growth potential, identify acquisition targets, and evaluate returns in the region's expanding diagnostic services sector.
- Clinical Laboratory Operators : Independent and hospital-based laboratory operators need market intelligence to plan service expansion, invest in new testing capabilities, and understand competitive dynamics in Latin America's cardiac marker testing market.
Key Companies in the Latin America Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Countries within Latin America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 418 Million |
| Mexico | USD 222.7 Million |
| Rest Of Latin America | USD 37.6 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation Data : Gain detailed insights into Latin America's cardiac marker testing market with country-level breakdowns for Brazil, Mexico, and Rest of Latin America. Understand market dynamics specific to each major economy and identify high-growth opportunities within the region.
- Competitive Landscape Analysis : Access comprehensive competitive intelligence on diagnostic companies operating in Latin America's cardiac marker testing space. Identify market leaders, emerging players, and partnership opportunities tailored to regional healthcare systems and regulatory environments.
- Growth Driver Identification : Understand the specific factors driving 9.2% CAGR growth in Latin America, including cardiovascular disease prevalence trends, healthcare infrastructure investments, and technology adoption rates. Make informed strategic decisions based on region-specific market dynamics.
- Market Entry & Expansion Strategy : Develop targeted market entry strategies for Latin America with insights into regulatory requirements, reimbursement landscapes, and healthcare provider preferences. Identify optimal geographic markets and customer segments for product launches and expansion.
- Forecast-Driven Planning : Leverage accurate 2031 market projections (USD 678.2 million) to guide long-term business planning, resource allocation, and investment decisions. Plan capacity expansion and product development roadmaps aligned with Latin America's anticipated market growth trajectory.
Frequently asked questions
What is the projected market size for cardiac marker testing in Latin America by 2031?
Latin America's cardiac marker testing market is projected to reach USD 678.2 million by 2031, growing from USD 436.9 million in 2026 at a 9.2% CAGR.
Which countries drive the largest share of Latin America's cardiac marker testing market?
Brazil, Mexico, and Argentina are the primary growth engines in Latin America, accounting for the majority of market volume and revenue due to their large populations and expanding healthcare infrastructure.
What testing technologies are most in demand across Latin America?
High-sensitivity troponin assays, B-type natriuretic peptide (BNP) tests, and multiplex biomarker platforms are experiencing the highest adoption rates in Latin America's healthcare systems.
How is Latin America's regulatory environment affecting cardiac marker testing adoption?
Regulatory harmonization and improved reimbursement policies across Latin America are facilitating faster adoption of advanced cardiac biomarker testing in both public and private healthcare facilities.
What factors are driving growth in Latin America's cardiac marker testing market?
Key drivers in Latin America include rising cardiovascular disease prevalence, increased healthcare spending, point-of-care testing adoption, digital health integration, and improved diagnostic awareness among healthcare providers.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report